Global Biological Vaccines Adjuvants Market Growth 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Biological Vaccines Adjuvants market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Biological Vaccines Adjuvants Industry Forecast” looks at past sales and reviews total world Biological Vaccines Adjuvants sales in 2024, providing a comprehensive analysis by region and market sector of projected Biological Vaccines Adjuvants sales for 2025 through 2031. With Biological Vaccines Adjuvants sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biological Vaccines Adjuvants industry.
This Insight Report provides a comprehensive analysis of the global Biological Vaccines Adjuvants landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biological Vaccines Adjuvants portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biological Vaccines Adjuvants market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biological Vaccines Adjuvants and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biological Vaccines Adjuvants.
This report presents a comprehensive overview, market shares, and growth opportunities of Biological Vaccines Adjuvants market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Biological Vaccines Adjuvants market?
What factors are driving Biological Vaccines Adjuvants market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Biological Vaccines Adjuvants market opportunities vary by end market size?
How does Biological Vaccines Adjuvants break out by Type, by Application?
The global Biological Vaccines Adjuvants market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Biological Vaccines Adjuvants Industry Forecast” looks at past sales and reviews total world Biological Vaccines Adjuvants sales in 2024, providing a comprehensive analysis by region and market sector of projected Biological Vaccines Adjuvants sales for 2025 through 2031. With Biological Vaccines Adjuvants sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biological Vaccines Adjuvants industry.
This Insight Report provides a comprehensive analysis of the global Biological Vaccines Adjuvants landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biological Vaccines Adjuvants portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biological Vaccines Adjuvants market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biological Vaccines Adjuvants and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biological Vaccines Adjuvants.
This report presents a comprehensive overview, market shares, and growth opportunities of Biological Vaccines Adjuvants market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Aluminum Adjuvant
- Emulsions Adjuvant
- Others
- Human Vaccine
- Veterinary Vaccine
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GSK
- Dynavax Technologies
- Novavax
- Agenus
- Croda International
- Seppic
- OZ Biosciences
- Phibro Animal Health Corporation
- Associated British Foods
- InvivoGen
- Merck KGaA
- CSL Limited
- Vertellus
- Allergy Therapeutics
- Riboxx GmbH
- CaPtivat? Pharmaceuticals
- EuBiologics
- Pacific GeneTech
- Hawaii Biotech
- Vaxine Pty Ltd.
- Creative Diagnostics
- LiteVax BV
- Mukta Industries
- Oncovir
- TiterMax USA
What is the 10-year outlook for the global Biological Vaccines Adjuvants market?
What factors are driving Biological Vaccines Adjuvants market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Biological Vaccines Adjuvants market opportunities vary by end market size?
How does Biological Vaccines Adjuvants break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Biological Vaccines Adjuvants Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Biological Vaccines Adjuvants by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Biological Vaccines Adjuvants by Country/Region, 2020, 2024 & 2031
2.2 Biological Vaccines Adjuvants Segment by Type
2.2.1 Aluminum Adjuvant
2.2.2 Emulsions Adjuvant
2.2.3 Others
2.3 Biological Vaccines Adjuvants Sales by Type
2.3.1 Global Biological Vaccines Adjuvants Sales Market Share by Type (2020-2025)
2.3.2 Global Biological Vaccines Adjuvants Revenue and Market Share by Type (2020-2025)
2.3.3 Global Biological Vaccines Adjuvants Sale Price by Type (2020-2025)
2.4 Biological Vaccines Adjuvants Segment by Application
2.4.1 Human Vaccine
2.4.2 Veterinary Vaccine
2.5 Biological Vaccines Adjuvants Sales by Application
2.5.1 Global Biological Vaccines Adjuvants Sale Market Share by Application (2020-2025)
2.5.2 Global Biological Vaccines Adjuvants Revenue and Market Share by Application (2020-2025)
2.5.3 Global Biological Vaccines Adjuvants Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Biological Vaccines Adjuvants Breakdown Data by Company
3.1.1 Global Biological Vaccines Adjuvants Annual Sales by Company (2020-2025)
3.1.2 Global Biological Vaccines Adjuvants Sales Market Share by Company (2020-2025)
3.2 Global Biological Vaccines Adjuvants Annual Revenue by Company (2020-2025)
3.2.1 Global Biological Vaccines Adjuvants Revenue by Company (2020-2025)
3.2.2 Global Biological Vaccines Adjuvants Revenue Market Share by Company (2020-2025)
3.3 Global Biological Vaccines Adjuvants Sale Price by Company
3.4 Key Manufacturers Biological Vaccines Adjuvants Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biological Vaccines Adjuvants Product Location Distribution
3.4.2 Players Biological Vaccines Adjuvants Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR BIOLOGICAL VACCINES ADJUVANTS BY GEOGRAPHIC REGION
4.1 World Historic Biological Vaccines Adjuvants Market Size by Geographic Region (2020-2025)
4.1.1 Global Biological Vaccines Adjuvants Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Biological Vaccines Adjuvants Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Biological Vaccines Adjuvants Market Size by Country/Region (2020-2025)
4.2.1 Global Biological Vaccines Adjuvants Annual Sales by Country/Region (2020-2025)
4.2.2 Global Biological Vaccines Adjuvants Annual Revenue by Country/Region (2020-2025)
4.3 Americas Biological Vaccines Adjuvants Sales Growth
4.4 APAC Biological Vaccines Adjuvants Sales Growth
4.5 Europe Biological Vaccines Adjuvants Sales Growth
4.6 Middle East & Africa Biological Vaccines Adjuvants Sales Growth
5 AMERICAS
5.1 Americas Biological Vaccines Adjuvants Sales by Country
5.1.1 Americas Biological Vaccines Adjuvants Sales by Country (2020-2025)
5.1.2 Americas Biological Vaccines Adjuvants Revenue by Country (2020-2025)
5.2 Americas Biological Vaccines Adjuvants Sales by Type (2020-2025)
5.3 Americas Biological Vaccines Adjuvants Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biological Vaccines Adjuvants Sales by Region
6.1.1 APAC Biological Vaccines Adjuvants Sales by Region (2020-2025)
6.1.2 APAC Biological Vaccines Adjuvants Revenue by Region (2020-2025)
6.2 APAC Biological Vaccines Adjuvants Sales by Type (2020-2025)
6.3 APAC Biological Vaccines Adjuvants Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Biological Vaccines Adjuvants by Country
7.1.1 Europe Biological Vaccines Adjuvants Sales by Country (2020-2025)
7.1.2 Europe Biological Vaccines Adjuvants Revenue by Country (2020-2025)
7.2 Europe Biological Vaccines Adjuvants Sales by Type (2020-2025)
7.3 Europe Biological Vaccines Adjuvants Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Biological Vaccines Adjuvants by Country
8.1.1 Middle East & Africa Biological Vaccines Adjuvants Sales by Country (2020-2025)
8.1.2 Middle East & Africa Biological Vaccines Adjuvants Revenue by Country (2020-2025)
8.2 Middle East & Africa Biological Vaccines Adjuvants Sales by Type (2020-2025)
8.3 Middle East & Africa Biological Vaccines Adjuvants Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biological Vaccines Adjuvants
10.3 Manufacturing Process Analysis of Biological Vaccines Adjuvants
10.4 Industry Chain Structure of Biological Vaccines Adjuvants
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biological Vaccines Adjuvants Distributors
11.3 Biological Vaccines Adjuvants Customer
12 WORLD FORECAST REVIEW FOR BIOLOGICAL VACCINES ADJUVANTS BY GEOGRAPHIC REGION
12.1 Global Biological Vaccines Adjuvants Market Size Forecast by Region
12.1.1 Global Biological Vaccines Adjuvants Forecast by Region (2026-2031)
12.1.2 Global Biological Vaccines Adjuvants Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Biological Vaccines Adjuvants Forecast by Type (2026-2031)
12.7 Global Biological Vaccines Adjuvants Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Biological Vaccines Adjuvants Product Portfolios and Specifications
13.1.3 GSK Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Dynavax Technologies
13.2.1 Dynavax Technologies Company Information
13.2.2 Dynavax Technologies Biological Vaccines Adjuvants Product Portfolios and Specifications
13.2.3 Dynavax Technologies Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Dynavax Technologies Main Business Overview
13.2.5 Dynavax Technologies Latest Developments
13.3 Novavax
13.3.1 Novavax Company Information
13.3.2 Novavax Biological Vaccines Adjuvants Product Portfolios and Specifications
13.3.3 Novavax Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Novavax Main Business Overview
13.3.5 Novavax Latest Developments
13.4 Agenus
13.4.1 Agenus Company Information
13.4.2 Agenus Biological Vaccines Adjuvants Product Portfolios and Specifications
13.4.3 Agenus Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Agenus Main Business Overview
13.4.5 Agenus Latest Developments
13.5 Croda International
13.5.1 Croda International Company Information
13.5.2 Croda International Biological Vaccines Adjuvants Product Portfolios and Specifications
13.5.3 Croda International Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Croda International Main Business Overview
13.5.5 Croda International Latest Developments
13.6 Seppic
13.6.1 Seppic Company Information
13.6.2 Seppic Biological Vaccines Adjuvants Product Portfolios and Specifications
13.6.3 Seppic Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Seppic Main Business Overview
13.6.5 Seppic Latest Developments
13.7 OZ Biosciences
13.7.1 OZ Biosciences Company Information
13.7.2 OZ Biosciences Biological Vaccines Adjuvants Product Portfolios and Specifications
13.7.3 OZ Biosciences Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 OZ Biosciences Main Business Overview
13.7.5 OZ Biosciences Latest Developments
13.8 Phibro Animal Health Corporation
13.8.1 Phibro Animal Health Corporation Company Information
13.8.2 Phibro Animal Health Corporation Biological Vaccines Adjuvants Product Portfolios and Specifications
13.8.3 Phibro Animal Health Corporation Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Phibro Animal Health Corporation Main Business Overview
13.8.5 Phibro Animal Health Corporation Latest Developments
13.9 Associated British Foods
13.9.1 Associated British Foods Company Information
13.9.2 Associated British Foods Biological Vaccines Adjuvants Product Portfolios and Specifications
13.9.3 Associated British Foods Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Associated British Foods Main Business Overview
13.9.5 Associated British Foods Latest Developments
13.10 InvivoGen
13.10.1 InvivoGen Company Information
13.10.2 InvivoGen Biological Vaccines Adjuvants Product Portfolios and Specifications
13.10.3 InvivoGen Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 InvivoGen Main Business Overview
13.10.5 InvivoGen Latest Developments
13.11 Merck KGaA
13.11.1 Merck KGaA Company Information
13.11.2 Merck KGaA Biological Vaccines Adjuvants Product Portfolios and Specifications
13.11.3 Merck KGaA Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Merck KGaA Main Business Overview
13.11.5 Merck KGaA Latest Developments
13.12 CSL Limited
13.12.1 CSL Limited Company Information
13.12.2 CSL Limited Biological Vaccines Adjuvants Product Portfolios and Specifications
13.12.3 CSL Limited Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 CSL Limited Main Business Overview
13.12.5 CSL Limited Latest Developments
13.13 Vertellus
13.13.1 Vertellus Company Information
13.13.2 Vertellus Biological Vaccines Adjuvants Product Portfolios and Specifications
13.13.3 Vertellus Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Vertellus Main Business Overview
13.13.5 Vertellus Latest Developments
13.14 Allergy Therapeutics
13.14.1 Allergy Therapeutics Company Information
13.14.2 Allergy Therapeutics Biological Vaccines Adjuvants Product Portfolios and Specifications
13.14.3 Allergy Therapeutics Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Allergy Therapeutics Main Business Overview
13.14.5 Allergy Therapeutics Latest Developments
13.15 Riboxx GmbH
13.15.1 Riboxx GmbH Company Information
13.15.2 Riboxx GmbH Biological Vaccines Adjuvants Product Portfolios and Specifications
13.15.3 Riboxx GmbH Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Riboxx GmbH Main Business Overview
13.15.5 Riboxx GmbH Latest Developments
13.16 CaPtivat? Pharmaceuticals
13.16.1 CaPtivat? Pharmaceuticals Company Information
13.16.2 CaPtivat? Pharmaceuticals Biological Vaccines Adjuvants Product Portfolios and Specifications
13.16.3 CaPtivat? Pharmaceuticals Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 CaPtivat? Pharmaceuticals Main Business Overview
13.16.5 CaPtivat? Pharmaceuticals Latest Developments
13.17 EuBiologics
13.17.1 EuBiologics Company Information
13.17.2 EuBiologics Biological Vaccines Adjuvants Product Portfolios and Specifications
13.17.3 EuBiologics Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 EuBiologics Main Business Overview
13.17.5 EuBiologics Latest Developments
13.18 Pacific GeneTech
13.18.1 Pacific GeneTech Company Information
13.18.2 Pacific GeneTech Biological Vaccines Adjuvants Product Portfolios and Specifications
13.18.3 Pacific GeneTech Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Pacific GeneTech Main Business Overview
13.18.5 Pacific GeneTech Latest Developments
13.19 Hawaii Biotech
13.19.1 Hawaii Biotech Company Information
13.19.2 Hawaii Biotech Biological Vaccines Adjuvants Product Portfolios and Specifications
13.19.3 Hawaii Biotech Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Hawaii Biotech Main Business Overview
13.19.5 Hawaii Biotech Latest Developments
13.20 Vaxine Pty Ltd.
13.20.1 Vaxine Pty Ltd. Company Information
13.20.2 Vaxine Pty Ltd. Biological Vaccines Adjuvants Product Portfolios and Specifications
13.20.3 Vaxine Pty Ltd. Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Vaxine Pty Ltd. Main Business Overview
13.20.5 Vaxine Pty Ltd. Latest Developments
13.21 Creative Diagnostics
13.21.1 Creative Diagnostics Company Information
13.21.2 Creative Diagnostics Biological Vaccines Adjuvants Product Portfolios and Specifications
13.21.3 Creative Diagnostics Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.21.4 Creative Diagnostics Main Business Overview
13.21.5 Creative Diagnostics Latest Developments
13.22 LiteVax BV
13.22.1 LiteVax BV Company Information
13.22.2 LiteVax BV Biological Vaccines Adjuvants Product Portfolios and Specifications
13.22.3 LiteVax BV Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.22.4 LiteVax BV Main Business Overview
13.22.5 LiteVax BV Latest Developments
13.23 Mukta Industries
13.23.1 Mukta Industries Company Information
13.23.2 Mukta Industries Biological Vaccines Adjuvants Product Portfolios and Specifications
13.23.3 Mukta Industries Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.23.4 Mukta Industries Main Business Overview
13.23.5 Mukta Industries Latest Developments
13.24 Oncovir
13.24.1 Oncovir Company Information
13.24.2 Oncovir Biological Vaccines Adjuvants Product Portfolios and Specifications
13.24.3 Oncovir Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.24.4 Oncovir Main Business Overview
13.24.5 Oncovir Latest Developments
13.25 TiterMax USA
13.25.1 TiterMax USA Company Information
13.25.2 TiterMax USA Biological Vaccines Adjuvants Product Portfolios and Specifications
13.25.3 TiterMax USA Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.25.4 TiterMax USA Main Business Overview
13.25.5 TiterMax USA Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Biological Vaccines Adjuvants Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Biological Vaccines Adjuvants Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Aluminum Adjuvant
Table 4. Major Players of Emulsions Adjuvant
Table 5. Major Players of Others
Table 6. Global Biological Vaccines Adjuvants Sales byType (2020-2025) & (K Units)
Table 7. Global Biological Vaccines Adjuvants Sales Market Share byType (2020-2025)
Table 8. Global Biological Vaccines Adjuvants Revenue byType (2020-2025) & ($ million)
Table 9. Global Biological Vaccines Adjuvants Revenue Market Share byType (2020-2025)
Table 10. Global Biological Vaccines Adjuvants Sale Price byType (2020-2025) & (US$/Unit)
Table 11. Global Biological Vaccines Adjuvants Sale by Application (2020-2025) & (K Units)
Table 12. Global Biological Vaccines Adjuvants Sale Market Share by Application (2020-2025)
Table 13. Global Biological Vaccines Adjuvants Revenue by Application (2020-2025) & ($ million)
Table 14. Global Biological Vaccines Adjuvants Revenue Market Share by Application (2020-2025)
Table 15. Global Biological Vaccines Adjuvants Sale Price by Application (2020-2025) & (US$/Unit)
Table 16. Global Biological Vaccines Adjuvants Sales by Company (2020-2025) & (K Units)
Table 17. Global Biological Vaccines Adjuvants Sales Market Share by Company (2020-2025)
Table 18. Global Biological Vaccines Adjuvants Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Biological Vaccines Adjuvants Revenue Market Share by Company (2020-2025)
Table 20. Global Biological Vaccines Adjuvants Sale Price by Company (2020-2025) & (US$/Unit)
Table 21. Key Manufacturers Biological Vaccines Adjuvants Producing Area Distribution and Sales Area
Table 22. Players Biological Vaccines Adjuvants Products Offered
Table 23. Biological Vaccines Adjuvants Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Biological Vaccines Adjuvants Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global Biological Vaccines Adjuvants Sales Market Share Geographic Region (2020-2025)
Table 28. Global Biological Vaccines Adjuvants Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Biological Vaccines Adjuvants Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Biological Vaccines Adjuvants Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global Biological Vaccines Adjuvants Sales Market Share by Country/Region (2020-2025)
Table 32. Global Biological Vaccines Adjuvants Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Biological Vaccines Adjuvants Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Biological Vaccines Adjuvants Sales by Country (2020-2025) & (K Units)
Table 35. Americas Biological Vaccines Adjuvants Sales Market Share by Country (2020-2025)
Table 36. Americas Biological Vaccines Adjuvants Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Biological Vaccines Adjuvants Sales byType (2020-2025) & (K Units)
Table 38. Americas Biological Vaccines Adjuvants Sales by Application (2020-2025) & (K Units)
Table 39. APAC Biological Vaccines Adjuvants Sales by Region (2020-2025) & (K Units)
Table 40. APAC Biological Vaccines Adjuvants Sales Market Share by Region (2020-2025)
Table 41. APAC Biological Vaccines Adjuvants Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Biological Vaccines Adjuvants Sales byType (2020-2025) & (K Units)
Table 43. APAC Biological Vaccines Adjuvants Sales by Application (2020-2025) & (K Units)
Table 44. Europe Biological Vaccines Adjuvants Sales by Country (2020-2025) & (K Units)
Table 45. Europe Biological Vaccines Adjuvants Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Biological Vaccines Adjuvants Sales byType (2020-2025) & (K Units)
Table 47. Europe Biological Vaccines Adjuvants Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa Biological Vaccines Adjuvants Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa Biological Vaccines Adjuvants Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Biological Vaccines Adjuvants Sales byType (2020-2025) & (K Units)
Table 51. Middle East & Africa Biological Vaccines Adjuvants Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Biological Vaccines Adjuvants
Table 53. Key Market Challenges & Risks of Biological Vaccines Adjuvants
Table 54. Key IndustryTrends of Biological Vaccines Adjuvants
Table 55. Biological Vaccines Adjuvants Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Biological Vaccines Adjuvants Distributors List
Table 58. Biological Vaccines Adjuvants Customer List
Table 59. Global Biological Vaccines Adjuvants SalesForecast by Region (2026-2031) & (K Units)
Table 60. Global Biological Vaccines Adjuvants RevenueForecast by Region (2026-2031) & ($ millions)
Table 61. Americas Biological Vaccines Adjuvants SalesForecast by Country (2026-2031) & (K Units)
Table 62. Americas Biological Vaccines Adjuvants Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 63. APAC Biological Vaccines Adjuvants SalesForecast by Region (2026-2031) & (K Units)
Table 64. APAC Biological Vaccines Adjuvants Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 65. Europe Biological Vaccines Adjuvants SalesForecast by Country (2026-2031) & (K Units)
Table 66. Europe Biological Vaccines Adjuvants RevenueForecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Biological Vaccines Adjuvants SalesForecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa Biological Vaccines Adjuvants RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. Global Biological Vaccines Adjuvants SalesForecast byType (2026-2031) & (K Units)
Table 70. Global Biological Vaccines Adjuvants RevenueForecast byType (2026-2031) & ($ millions)
Table 71. Global Biological Vaccines Adjuvants SalesForecast by Application (2026-2031) & (K Units)
Table 72. Global Biological Vaccines Adjuvants RevenueForecast by Application (2026-2031) & ($ millions)
Table 73. GSK Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 74. GSK Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 75. GSK Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 76. GSK Main Business
Table 77. GSK Latest Developments
Table 78. DynavaxTechnologies Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 79. DynavaxTechnologies Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 80. DynavaxTechnologies Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. DynavaxTechnologies Main Business
Table 82. DynavaxTechnologies Latest Developments
Table 83. Novavax Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 84. Novavax Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 85. Novavax Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 86. Novavax Main Business
Table 87. Novavax Latest Developments
Table 88. Agenus Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 89. Agenus Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 90. Agenus Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 91. Agenus Main Business
Table 92. Agenus Latest Developments
Table 93. Croda International Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 94. Croda International Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 95. Croda International Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 96. Croda International Main Business
Table 97. Croda International Latest Developments
Table 98. Seppic Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 99. Seppic Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 100. Seppic Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 101. Seppic Main Business
Table 102. Seppic Latest Developments
Table 103. OZ Biosciences Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 104. OZ Biosciences Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 105. OZ Biosciences Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 106. OZ Biosciences Main Business
Table 107. OZ Biosciences Latest Developments
Table 108. Phibro Animal Health Corporation Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 109. Phibro Animal Health Corporation Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 110. Phibro Animal Health Corporation Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 111. Phibro Animal Health Corporation Main Business
Table 112. Phibro Animal Health Corporation Latest Developments
Table 113. Associated BritishFoods Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 114. Associated BritishFoods Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 115. Associated BritishFoods Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 116. Associated BritishFoods Main Business
Table 117. Associated BritishFoods Latest Developments
Table 118. InvivoGen Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 119. InvivoGen Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 120. InvivoGen Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 121. InvivoGen Main Business
Table 122. InvivoGen Latest Developments
Table 123. Merck KGaA Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 124. Merck KGaA Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 125. Merck KGaA Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 126. Merck KGaA Main Business
Table 127. Merck KGaA Latest Developments
Table 128. CSL Limited Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 129. CSL Limited Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 130. CSL Limited Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 131. CSL Limited Main Business
Table 132. CSL Limited Latest Developments
Table 133. Vertellus Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 134. Vertellus Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 135. Vertellus Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 136. Vertellus Main Business
Table 137. Vertellus Latest Developments
Table 138. AllergyTherapeutics Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 139. AllergyTherapeutics Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 140. AllergyTherapeutics Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 141. AllergyTherapeutics Main Business
Table 142. AllergyTherapeutics Latest Developments
Table 143. Riboxx GmbH Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 144. Riboxx GmbH Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 145. Riboxx GmbH Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 146. Riboxx GmbH Main Business
Table 147. Riboxx GmbH Latest Developments
Table 148. CaPtivat? Pharmaceuticals Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 149. CaPtivat? Pharmaceuticals Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 150. CaPtivat? Pharmaceuticals Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 151. CaPtivat? Pharmaceuticals Main Business
Table 152. CaPtivat? Pharmaceuticals Latest Developments
Table 153. EuBiologics Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 154. EuBiologics Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 155. EuBiologics Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 156. EuBiologics Main Business
Table 157. EuBiologics Latest Developments
Table 158. Pacific GeneTech Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 159. Pacific GeneTech Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 160. Pacific GeneTech Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 161. Pacific GeneTech Main Business
Table 162. Pacific GeneTech Latest Developments
Table 163. Hawaii Biotech Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 164. Hawaii Biotech Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 165. Hawaii Biotech Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 166. Hawaii Biotech Main Business
Table 167. Hawaii Biotech Latest Developments
Table 168. Vaxine Pty Ltd. Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 169. Vaxine Pty Ltd. Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 170. Vaxine Pty Ltd. Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 171. Vaxine Pty Ltd. Main Business
Table 172. Vaxine Pty Ltd. Latest Developments
Table 173. Creative Diagnostics Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 174. Creative Diagnostics Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 175. Creative Diagnostics Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 176. Creative Diagnostics Main Business
Table 177. Creative Diagnostics Latest Developments
Table 178. LiteVax BV Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 179. LiteVax BV Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 180. LiteVax BV Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 181. LiteVax BV Main Business
Table 182. LiteVax BV Latest Developments
Table 183. Mukta Industries Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 184. Mukta Industries Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 185. Mukta Industries Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 186. Mukta Industries Main Business
Table 187. Mukta Industries Latest Developments
Table 188. Oncovir Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 189. Oncovir Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 190. Oncovir Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 191. Oncovir Main Business
Table 192. Oncovir Latest Developments
Table 193.TiterMax USA Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 194.TiterMax USA Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 195.TiterMax USA Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 196.TiterMax USA Main Business
Table 197.TiterMax USA Latest Developments
LIST OFFIGURES
Figure 1. Picture of Biological Vaccines Adjuvants
Figure 2. Biological Vaccines Adjuvants Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Biological Vaccines Adjuvants Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Biological Vaccines Adjuvants Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Biological Vaccines Adjuvants Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Biological Vaccines Adjuvants Sales Market Share by Country/Region (2024)
Figure 10. Biological Vaccines Adjuvants Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Aluminum Adjuvant
Figure 12. Product Picture of Emulsions Adjuvant
Figure 13. Product Picture of Others
Figure 14. Global Biological Vaccines Adjuvants Sales Market Share byType in 2025
Figure 15. Global Biological Vaccines Adjuvants Revenue Market Share byType (2020-2025)
Figure 16. Biological Vaccines Adjuvants Consumed in Human Vaccine
Figure 17. Global Biological Vaccines Adjuvants Market: Human Vaccine (2020-2025) & (K Units)
Figure 18. Biological Vaccines Adjuvants Consumed in Veterinary Vaccine
Figure 19. Global Biological Vaccines Adjuvants Market: Veterinary Vaccine (2020-2025) & (K Units)
Figure 20. Global Biological Vaccines Adjuvants Sale Market Share by Application (2024)
Figure 21. Global Biological Vaccines Adjuvants Revenue Market Share by Application in 2025
Figure 22. Biological Vaccines Adjuvants Sales by Company in 2025 (K Units)
Figure 23. Global Biological Vaccines Adjuvants Sales Market Share by Company in 2025
Figure 24. Biological Vaccines Adjuvants Revenue by Company in 2025 ($ millions)
Figure 25. Global Biological Vaccines Adjuvants Revenue Market Share by Company in 2025
Figure 26. Global Biological Vaccines Adjuvants Sales Market Share by Geographic Region (2020-2025)
Figure 27. Global Biological Vaccines Adjuvants Revenue Market Share by Geographic Region in 2025
Figure 28. Americas Biological Vaccines Adjuvants Sales 2020-2025 (K Units)
Figure 29. Americas Biological Vaccines Adjuvants Revenue 2020-2025 ($ millions)
Figure 30. APAC Biological Vaccines Adjuvants Sales 2020-2025 (K Units)
Figure 31. APAC Biological Vaccines Adjuvants Revenue 2020-2025 ($ millions)
Figure 32. Europe Biological Vaccines Adjuvants Sales 2020-2025 (K Units)
Figure 33. Europe Biological Vaccines Adjuvants Revenue 2020-2025 ($ millions)
Figure 34. Middle East & Africa Biological Vaccines Adjuvants Sales 2020-2025 (K Units)
Figure 35. Middle East & Africa Biological Vaccines Adjuvants Revenue 2020-2025 ($ millions)
Figure 36. Americas Biological Vaccines Adjuvants Sales Market Share by Country in 2025
Figure 37. Americas Biological Vaccines Adjuvants Revenue Market Share by Country (2020-2025)
Figure 38. Americas Biological Vaccines Adjuvants Sales Market Share byType (2020-2025)
Figure 39. Americas Biological Vaccines Adjuvants Sales Market Share by Application (2020-2025)
Figure 40. United States Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 41. Canada Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 42. Mexico Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 43. Brazil Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 44. APAC Biological Vaccines Adjuvants Sales Market Share by Region in 2025
Figure 45. APAC Biological Vaccines Adjuvants Revenue Market Share by Region (2020-2025)
Figure 46. APAC Biological Vaccines Adjuvants Sales Market Share byType (2020-2025)
Figure 47. APAC Biological Vaccines Adjuvants Sales Market Share by Application (2020-2025)
Figure 48. China Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 49. Japan Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 50. South Korea Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 51. Southeast Asia Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 52. India Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 53. Australia Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 54. ChinaTaiwan Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 55. Europe Biological Vaccines Adjuvants Sales Market Share by Country in 2025
Figure 56. Europe Biological Vaccines Adjuvants Revenue Market Share by Country (2020-2025)
Figure 57. Europe Biological Vaccines Adjuvants Sales Market Share byType (2020-2025)
Figure 58. Europe Biological Vaccines Adjuvants Sales Market Share by Application (2020-2025)
Figure 59. Germany Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 60.France Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 61. UK Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 62. Italy Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 63. Russia Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 64. Middle East & Africa Biological Vaccines Adjuvants Sales Market Share by Country (2020-2025)
Figure 65. Middle East & Africa Biological Vaccines Adjuvants Sales Market Share byType (2020-2025)
Figure 66. Middle East & Africa Biological Vaccines Adjuvants Sales Market Share by Application (2020-2025)
Figure 67. Egypt Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 68. South Africa Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 69. Israel Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 70.Turkey Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 71. GCC Countries Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 72. Manufacturing Cost Structure Analysis of Biological Vaccines Adjuvants in 2025
Figure 73. Manufacturing Process Analysis of Biological Vaccines Adjuvants
Figure 74. Industry Chain Structure of Biological Vaccines Adjuvants
Figure 75. Channels of Distribution
Figure 76. Global Biological Vaccines Adjuvants Sales MarketForecast by Region (2026-2031)
Figure 77. Global Biological Vaccines Adjuvants Revenue Market ShareForecast by Region (2026-2031)
Figure 78. Global Biological Vaccines Adjuvants Sales Market ShareForecast byType (2026-2031)
Figure 79. Global Biological Vaccines Adjuvants Revenue Market ShareForecast byType (2026-2031)
Figure 80. Global Biological Vaccines Adjuvants Sales Market ShareForecast by Application (2026-2031)
Figure 81. Global Biological Vaccines Adjuvants Revenue Market ShareForecast by Application (2026-2031)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Biological Vaccines Adjuvants Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Biological Vaccines Adjuvants by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Biological Vaccines Adjuvants by Country/Region, 2020, 2024 & 2031
2.2 Biological Vaccines Adjuvants Segment by Type
2.2.1 Aluminum Adjuvant
2.2.2 Emulsions Adjuvant
2.2.3 Others
2.3 Biological Vaccines Adjuvants Sales by Type
2.3.1 Global Biological Vaccines Adjuvants Sales Market Share by Type (2020-2025)
2.3.2 Global Biological Vaccines Adjuvants Revenue and Market Share by Type (2020-2025)
2.3.3 Global Biological Vaccines Adjuvants Sale Price by Type (2020-2025)
2.4 Biological Vaccines Adjuvants Segment by Application
2.4.1 Human Vaccine
2.4.2 Veterinary Vaccine
2.5 Biological Vaccines Adjuvants Sales by Application
2.5.1 Global Biological Vaccines Adjuvants Sale Market Share by Application (2020-2025)
2.5.2 Global Biological Vaccines Adjuvants Revenue and Market Share by Application (2020-2025)
2.5.3 Global Biological Vaccines Adjuvants Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Biological Vaccines Adjuvants Breakdown Data by Company
3.1.1 Global Biological Vaccines Adjuvants Annual Sales by Company (2020-2025)
3.1.2 Global Biological Vaccines Adjuvants Sales Market Share by Company (2020-2025)
3.2 Global Biological Vaccines Adjuvants Annual Revenue by Company (2020-2025)
3.2.1 Global Biological Vaccines Adjuvants Revenue by Company (2020-2025)
3.2.2 Global Biological Vaccines Adjuvants Revenue Market Share by Company (2020-2025)
3.3 Global Biological Vaccines Adjuvants Sale Price by Company
3.4 Key Manufacturers Biological Vaccines Adjuvants Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biological Vaccines Adjuvants Product Location Distribution
3.4.2 Players Biological Vaccines Adjuvants Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR BIOLOGICAL VACCINES ADJUVANTS BY GEOGRAPHIC REGION
4.1 World Historic Biological Vaccines Adjuvants Market Size by Geographic Region (2020-2025)
4.1.1 Global Biological Vaccines Adjuvants Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Biological Vaccines Adjuvants Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Biological Vaccines Adjuvants Market Size by Country/Region (2020-2025)
4.2.1 Global Biological Vaccines Adjuvants Annual Sales by Country/Region (2020-2025)
4.2.2 Global Biological Vaccines Adjuvants Annual Revenue by Country/Region (2020-2025)
4.3 Americas Biological Vaccines Adjuvants Sales Growth
4.4 APAC Biological Vaccines Adjuvants Sales Growth
4.5 Europe Biological Vaccines Adjuvants Sales Growth
4.6 Middle East & Africa Biological Vaccines Adjuvants Sales Growth
5 AMERICAS
5.1 Americas Biological Vaccines Adjuvants Sales by Country
5.1.1 Americas Biological Vaccines Adjuvants Sales by Country (2020-2025)
5.1.2 Americas Biological Vaccines Adjuvants Revenue by Country (2020-2025)
5.2 Americas Biological Vaccines Adjuvants Sales by Type (2020-2025)
5.3 Americas Biological Vaccines Adjuvants Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biological Vaccines Adjuvants Sales by Region
6.1.1 APAC Biological Vaccines Adjuvants Sales by Region (2020-2025)
6.1.2 APAC Biological Vaccines Adjuvants Revenue by Region (2020-2025)
6.2 APAC Biological Vaccines Adjuvants Sales by Type (2020-2025)
6.3 APAC Biological Vaccines Adjuvants Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Biological Vaccines Adjuvants by Country
7.1.1 Europe Biological Vaccines Adjuvants Sales by Country (2020-2025)
7.1.2 Europe Biological Vaccines Adjuvants Revenue by Country (2020-2025)
7.2 Europe Biological Vaccines Adjuvants Sales by Type (2020-2025)
7.3 Europe Biological Vaccines Adjuvants Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Biological Vaccines Adjuvants by Country
8.1.1 Middle East & Africa Biological Vaccines Adjuvants Sales by Country (2020-2025)
8.1.2 Middle East & Africa Biological Vaccines Adjuvants Revenue by Country (2020-2025)
8.2 Middle East & Africa Biological Vaccines Adjuvants Sales by Type (2020-2025)
8.3 Middle East & Africa Biological Vaccines Adjuvants Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biological Vaccines Adjuvants
10.3 Manufacturing Process Analysis of Biological Vaccines Adjuvants
10.4 Industry Chain Structure of Biological Vaccines Adjuvants
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biological Vaccines Adjuvants Distributors
11.3 Biological Vaccines Adjuvants Customer
12 WORLD FORECAST REVIEW FOR BIOLOGICAL VACCINES ADJUVANTS BY GEOGRAPHIC REGION
12.1 Global Biological Vaccines Adjuvants Market Size Forecast by Region
12.1.1 Global Biological Vaccines Adjuvants Forecast by Region (2026-2031)
12.1.2 Global Biological Vaccines Adjuvants Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Biological Vaccines Adjuvants Forecast by Type (2026-2031)
12.7 Global Biological Vaccines Adjuvants Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Biological Vaccines Adjuvants Product Portfolios and Specifications
13.1.3 GSK Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Dynavax Technologies
13.2.1 Dynavax Technologies Company Information
13.2.2 Dynavax Technologies Biological Vaccines Adjuvants Product Portfolios and Specifications
13.2.3 Dynavax Technologies Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Dynavax Technologies Main Business Overview
13.2.5 Dynavax Technologies Latest Developments
13.3 Novavax
13.3.1 Novavax Company Information
13.3.2 Novavax Biological Vaccines Adjuvants Product Portfolios and Specifications
13.3.3 Novavax Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Novavax Main Business Overview
13.3.5 Novavax Latest Developments
13.4 Agenus
13.4.1 Agenus Company Information
13.4.2 Agenus Biological Vaccines Adjuvants Product Portfolios and Specifications
13.4.3 Agenus Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Agenus Main Business Overview
13.4.5 Agenus Latest Developments
13.5 Croda International
13.5.1 Croda International Company Information
13.5.2 Croda International Biological Vaccines Adjuvants Product Portfolios and Specifications
13.5.3 Croda International Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Croda International Main Business Overview
13.5.5 Croda International Latest Developments
13.6 Seppic
13.6.1 Seppic Company Information
13.6.2 Seppic Biological Vaccines Adjuvants Product Portfolios and Specifications
13.6.3 Seppic Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Seppic Main Business Overview
13.6.5 Seppic Latest Developments
13.7 OZ Biosciences
13.7.1 OZ Biosciences Company Information
13.7.2 OZ Biosciences Biological Vaccines Adjuvants Product Portfolios and Specifications
13.7.3 OZ Biosciences Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 OZ Biosciences Main Business Overview
13.7.5 OZ Biosciences Latest Developments
13.8 Phibro Animal Health Corporation
13.8.1 Phibro Animal Health Corporation Company Information
13.8.2 Phibro Animal Health Corporation Biological Vaccines Adjuvants Product Portfolios and Specifications
13.8.3 Phibro Animal Health Corporation Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Phibro Animal Health Corporation Main Business Overview
13.8.5 Phibro Animal Health Corporation Latest Developments
13.9 Associated British Foods
13.9.1 Associated British Foods Company Information
13.9.2 Associated British Foods Biological Vaccines Adjuvants Product Portfolios and Specifications
13.9.3 Associated British Foods Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Associated British Foods Main Business Overview
13.9.5 Associated British Foods Latest Developments
13.10 InvivoGen
13.10.1 InvivoGen Company Information
13.10.2 InvivoGen Biological Vaccines Adjuvants Product Portfolios and Specifications
13.10.3 InvivoGen Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 InvivoGen Main Business Overview
13.10.5 InvivoGen Latest Developments
13.11 Merck KGaA
13.11.1 Merck KGaA Company Information
13.11.2 Merck KGaA Biological Vaccines Adjuvants Product Portfolios and Specifications
13.11.3 Merck KGaA Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Merck KGaA Main Business Overview
13.11.5 Merck KGaA Latest Developments
13.12 CSL Limited
13.12.1 CSL Limited Company Information
13.12.2 CSL Limited Biological Vaccines Adjuvants Product Portfolios and Specifications
13.12.3 CSL Limited Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 CSL Limited Main Business Overview
13.12.5 CSL Limited Latest Developments
13.13 Vertellus
13.13.1 Vertellus Company Information
13.13.2 Vertellus Biological Vaccines Adjuvants Product Portfolios and Specifications
13.13.3 Vertellus Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Vertellus Main Business Overview
13.13.5 Vertellus Latest Developments
13.14 Allergy Therapeutics
13.14.1 Allergy Therapeutics Company Information
13.14.2 Allergy Therapeutics Biological Vaccines Adjuvants Product Portfolios and Specifications
13.14.3 Allergy Therapeutics Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Allergy Therapeutics Main Business Overview
13.14.5 Allergy Therapeutics Latest Developments
13.15 Riboxx GmbH
13.15.1 Riboxx GmbH Company Information
13.15.2 Riboxx GmbH Biological Vaccines Adjuvants Product Portfolios and Specifications
13.15.3 Riboxx GmbH Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Riboxx GmbH Main Business Overview
13.15.5 Riboxx GmbH Latest Developments
13.16 CaPtivat? Pharmaceuticals
13.16.1 CaPtivat? Pharmaceuticals Company Information
13.16.2 CaPtivat? Pharmaceuticals Biological Vaccines Adjuvants Product Portfolios and Specifications
13.16.3 CaPtivat? Pharmaceuticals Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 CaPtivat? Pharmaceuticals Main Business Overview
13.16.5 CaPtivat? Pharmaceuticals Latest Developments
13.17 EuBiologics
13.17.1 EuBiologics Company Information
13.17.2 EuBiologics Biological Vaccines Adjuvants Product Portfolios and Specifications
13.17.3 EuBiologics Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 EuBiologics Main Business Overview
13.17.5 EuBiologics Latest Developments
13.18 Pacific GeneTech
13.18.1 Pacific GeneTech Company Information
13.18.2 Pacific GeneTech Biological Vaccines Adjuvants Product Portfolios and Specifications
13.18.3 Pacific GeneTech Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Pacific GeneTech Main Business Overview
13.18.5 Pacific GeneTech Latest Developments
13.19 Hawaii Biotech
13.19.1 Hawaii Biotech Company Information
13.19.2 Hawaii Biotech Biological Vaccines Adjuvants Product Portfolios and Specifications
13.19.3 Hawaii Biotech Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Hawaii Biotech Main Business Overview
13.19.5 Hawaii Biotech Latest Developments
13.20 Vaxine Pty Ltd.
13.20.1 Vaxine Pty Ltd. Company Information
13.20.2 Vaxine Pty Ltd. Biological Vaccines Adjuvants Product Portfolios and Specifications
13.20.3 Vaxine Pty Ltd. Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Vaxine Pty Ltd. Main Business Overview
13.20.5 Vaxine Pty Ltd. Latest Developments
13.21 Creative Diagnostics
13.21.1 Creative Diagnostics Company Information
13.21.2 Creative Diagnostics Biological Vaccines Adjuvants Product Portfolios and Specifications
13.21.3 Creative Diagnostics Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.21.4 Creative Diagnostics Main Business Overview
13.21.5 Creative Diagnostics Latest Developments
13.22 LiteVax BV
13.22.1 LiteVax BV Company Information
13.22.2 LiteVax BV Biological Vaccines Adjuvants Product Portfolios and Specifications
13.22.3 LiteVax BV Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.22.4 LiteVax BV Main Business Overview
13.22.5 LiteVax BV Latest Developments
13.23 Mukta Industries
13.23.1 Mukta Industries Company Information
13.23.2 Mukta Industries Biological Vaccines Adjuvants Product Portfolios and Specifications
13.23.3 Mukta Industries Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.23.4 Mukta Industries Main Business Overview
13.23.5 Mukta Industries Latest Developments
13.24 Oncovir
13.24.1 Oncovir Company Information
13.24.2 Oncovir Biological Vaccines Adjuvants Product Portfolios and Specifications
13.24.3 Oncovir Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.24.4 Oncovir Main Business Overview
13.24.5 Oncovir Latest Developments
13.25 TiterMax USA
13.25.1 TiterMax USA Company Information
13.25.2 TiterMax USA Biological Vaccines Adjuvants Product Portfolios and Specifications
13.25.3 TiterMax USA Biological Vaccines Adjuvants Sales, Revenue, Price and Gross Margin (2020-2025)
13.25.4 TiterMax USA Main Business Overview
13.25.5 TiterMax USA Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Biological Vaccines Adjuvants Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Biological Vaccines Adjuvants Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Aluminum Adjuvant
Table 4. Major Players of Emulsions Adjuvant
Table 5. Major Players of Others
Table 6. Global Biological Vaccines Adjuvants Sales byType (2020-2025) & (K Units)
Table 7. Global Biological Vaccines Adjuvants Sales Market Share byType (2020-2025)
Table 8. Global Biological Vaccines Adjuvants Revenue byType (2020-2025) & ($ million)
Table 9. Global Biological Vaccines Adjuvants Revenue Market Share byType (2020-2025)
Table 10. Global Biological Vaccines Adjuvants Sale Price byType (2020-2025) & (US$/Unit)
Table 11. Global Biological Vaccines Adjuvants Sale by Application (2020-2025) & (K Units)
Table 12. Global Biological Vaccines Adjuvants Sale Market Share by Application (2020-2025)
Table 13. Global Biological Vaccines Adjuvants Revenue by Application (2020-2025) & ($ million)
Table 14. Global Biological Vaccines Adjuvants Revenue Market Share by Application (2020-2025)
Table 15. Global Biological Vaccines Adjuvants Sale Price by Application (2020-2025) & (US$/Unit)
Table 16. Global Biological Vaccines Adjuvants Sales by Company (2020-2025) & (K Units)
Table 17. Global Biological Vaccines Adjuvants Sales Market Share by Company (2020-2025)
Table 18. Global Biological Vaccines Adjuvants Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Biological Vaccines Adjuvants Revenue Market Share by Company (2020-2025)
Table 20. Global Biological Vaccines Adjuvants Sale Price by Company (2020-2025) & (US$/Unit)
Table 21. Key Manufacturers Biological Vaccines Adjuvants Producing Area Distribution and Sales Area
Table 22. Players Biological Vaccines Adjuvants Products Offered
Table 23. Biological Vaccines Adjuvants Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Biological Vaccines Adjuvants Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global Biological Vaccines Adjuvants Sales Market Share Geographic Region (2020-2025)
Table 28. Global Biological Vaccines Adjuvants Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Biological Vaccines Adjuvants Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Biological Vaccines Adjuvants Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global Biological Vaccines Adjuvants Sales Market Share by Country/Region (2020-2025)
Table 32. Global Biological Vaccines Adjuvants Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Biological Vaccines Adjuvants Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Biological Vaccines Adjuvants Sales by Country (2020-2025) & (K Units)
Table 35. Americas Biological Vaccines Adjuvants Sales Market Share by Country (2020-2025)
Table 36. Americas Biological Vaccines Adjuvants Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Biological Vaccines Adjuvants Sales byType (2020-2025) & (K Units)
Table 38. Americas Biological Vaccines Adjuvants Sales by Application (2020-2025) & (K Units)
Table 39. APAC Biological Vaccines Adjuvants Sales by Region (2020-2025) & (K Units)
Table 40. APAC Biological Vaccines Adjuvants Sales Market Share by Region (2020-2025)
Table 41. APAC Biological Vaccines Adjuvants Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Biological Vaccines Adjuvants Sales byType (2020-2025) & (K Units)
Table 43. APAC Biological Vaccines Adjuvants Sales by Application (2020-2025) & (K Units)
Table 44. Europe Biological Vaccines Adjuvants Sales by Country (2020-2025) & (K Units)
Table 45. Europe Biological Vaccines Adjuvants Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Biological Vaccines Adjuvants Sales byType (2020-2025) & (K Units)
Table 47. Europe Biological Vaccines Adjuvants Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa Biological Vaccines Adjuvants Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa Biological Vaccines Adjuvants Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Biological Vaccines Adjuvants Sales byType (2020-2025) & (K Units)
Table 51. Middle East & Africa Biological Vaccines Adjuvants Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Biological Vaccines Adjuvants
Table 53. Key Market Challenges & Risks of Biological Vaccines Adjuvants
Table 54. Key IndustryTrends of Biological Vaccines Adjuvants
Table 55. Biological Vaccines Adjuvants Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Biological Vaccines Adjuvants Distributors List
Table 58. Biological Vaccines Adjuvants Customer List
Table 59. Global Biological Vaccines Adjuvants SalesForecast by Region (2026-2031) & (K Units)
Table 60. Global Biological Vaccines Adjuvants RevenueForecast by Region (2026-2031) & ($ millions)
Table 61. Americas Biological Vaccines Adjuvants SalesForecast by Country (2026-2031) & (K Units)
Table 62. Americas Biological Vaccines Adjuvants Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 63. APAC Biological Vaccines Adjuvants SalesForecast by Region (2026-2031) & (K Units)
Table 64. APAC Biological Vaccines Adjuvants Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 65. Europe Biological Vaccines Adjuvants SalesForecast by Country (2026-2031) & (K Units)
Table 66. Europe Biological Vaccines Adjuvants RevenueForecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Biological Vaccines Adjuvants SalesForecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa Biological Vaccines Adjuvants RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. Global Biological Vaccines Adjuvants SalesForecast byType (2026-2031) & (K Units)
Table 70. Global Biological Vaccines Adjuvants RevenueForecast byType (2026-2031) & ($ millions)
Table 71. Global Biological Vaccines Adjuvants SalesForecast by Application (2026-2031) & (K Units)
Table 72. Global Biological Vaccines Adjuvants RevenueForecast by Application (2026-2031) & ($ millions)
Table 73. GSK Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 74. GSK Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 75. GSK Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 76. GSK Main Business
Table 77. GSK Latest Developments
Table 78. DynavaxTechnologies Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 79. DynavaxTechnologies Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 80. DynavaxTechnologies Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. DynavaxTechnologies Main Business
Table 82. DynavaxTechnologies Latest Developments
Table 83. Novavax Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 84. Novavax Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 85. Novavax Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 86. Novavax Main Business
Table 87. Novavax Latest Developments
Table 88. Agenus Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 89. Agenus Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 90. Agenus Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 91. Agenus Main Business
Table 92. Agenus Latest Developments
Table 93. Croda International Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 94. Croda International Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 95. Croda International Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 96. Croda International Main Business
Table 97. Croda International Latest Developments
Table 98. Seppic Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 99. Seppic Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 100. Seppic Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 101. Seppic Main Business
Table 102. Seppic Latest Developments
Table 103. OZ Biosciences Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 104. OZ Biosciences Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 105. OZ Biosciences Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 106. OZ Biosciences Main Business
Table 107. OZ Biosciences Latest Developments
Table 108. Phibro Animal Health Corporation Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 109. Phibro Animal Health Corporation Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 110. Phibro Animal Health Corporation Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 111. Phibro Animal Health Corporation Main Business
Table 112. Phibro Animal Health Corporation Latest Developments
Table 113. Associated BritishFoods Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 114. Associated BritishFoods Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 115. Associated BritishFoods Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 116. Associated BritishFoods Main Business
Table 117. Associated BritishFoods Latest Developments
Table 118. InvivoGen Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 119. InvivoGen Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 120. InvivoGen Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 121. InvivoGen Main Business
Table 122. InvivoGen Latest Developments
Table 123. Merck KGaA Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 124. Merck KGaA Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 125. Merck KGaA Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 126. Merck KGaA Main Business
Table 127. Merck KGaA Latest Developments
Table 128. CSL Limited Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 129. CSL Limited Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 130. CSL Limited Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 131. CSL Limited Main Business
Table 132. CSL Limited Latest Developments
Table 133. Vertellus Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 134. Vertellus Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 135. Vertellus Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 136. Vertellus Main Business
Table 137. Vertellus Latest Developments
Table 138. AllergyTherapeutics Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 139. AllergyTherapeutics Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 140. AllergyTherapeutics Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 141. AllergyTherapeutics Main Business
Table 142. AllergyTherapeutics Latest Developments
Table 143. Riboxx GmbH Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 144. Riboxx GmbH Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 145. Riboxx GmbH Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 146. Riboxx GmbH Main Business
Table 147. Riboxx GmbH Latest Developments
Table 148. CaPtivat? Pharmaceuticals Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 149. CaPtivat? Pharmaceuticals Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 150. CaPtivat? Pharmaceuticals Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 151. CaPtivat? Pharmaceuticals Main Business
Table 152. CaPtivat? Pharmaceuticals Latest Developments
Table 153. EuBiologics Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 154. EuBiologics Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 155. EuBiologics Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 156. EuBiologics Main Business
Table 157. EuBiologics Latest Developments
Table 158. Pacific GeneTech Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 159. Pacific GeneTech Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 160. Pacific GeneTech Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 161. Pacific GeneTech Main Business
Table 162. Pacific GeneTech Latest Developments
Table 163. Hawaii Biotech Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 164. Hawaii Biotech Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 165. Hawaii Biotech Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 166. Hawaii Biotech Main Business
Table 167. Hawaii Biotech Latest Developments
Table 168. Vaxine Pty Ltd. Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 169. Vaxine Pty Ltd. Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 170. Vaxine Pty Ltd. Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 171. Vaxine Pty Ltd. Main Business
Table 172. Vaxine Pty Ltd. Latest Developments
Table 173. Creative Diagnostics Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 174. Creative Diagnostics Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 175. Creative Diagnostics Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 176. Creative Diagnostics Main Business
Table 177. Creative Diagnostics Latest Developments
Table 178. LiteVax BV Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 179. LiteVax BV Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 180. LiteVax BV Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 181. LiteVax BV Main Business
Table 182. LiteVax BV Latest Developments
Table 183. Mukta Industries Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 184. Mukta Industries Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 185. Mukta Industries Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 186. Mukta Industries Main Business
Table 187. Mukta Industries Latest Developments
Table 188. Oncovir Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 189. Oncovir Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 190. Oncovir Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 191. Oncovir Main Business
Table 192. Oncovir Latest Developments
Table 193.TiterMax USA Basic Information, Biological Vaccines Adjuvants Manufacturing Base, Sales Area and Its Competitors
Table 194.TiterMax USA Biological Vaccines Adjuvants Product Portfolios and Specifications
Table 195.TiterMax USA Biological Vaccines Adjuvants Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 196.TiterMax USA Main Business
Table 197.TiterMax USA Latest Developments
LIST OFFIGURES
Figure 1. Picture of Biological Vaccines Adjuvants
Figure 2. Biological Vaccines Adjuvants Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Biological Vaccines Adjuvants Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Biological Vaccines Adjuvants Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Biological Vaccines Adjuvants Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Biological Vaccines Adjuvants Sales Market Share by Country/Region (2024)
Figure 10. Biological Vaccines Adjuvants Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Aluminum Adjuvant
Figure 12. Product Picture of Emulsions Adjuvant
Figure 13. Product Picture of Others
Figure 14. Global Biological Vaccines Adjuvants Sales Market Share byType in 2025
Figure 15. Global Biological Vaccines Adjuvants Revenue Market Share byType (2020-2025)
Figure 16. Biological Vaccines Adjuvants Consumed in Human Vaccine
Figure 17. Global Biological Vaccines Adjuvants Market: Human Vaccine (2020-2025) & (K Units)
Figure 18. Biological Vaccines Adjuvants Consumed in Veterinary Vaccine
Figure 19. Global Biological Vaccines Adjuvants Market: Veterinary Vaccine (2020-2025) & (K Units)
Figure 20. Global Biological Vaccines Adjuvants Sale Market Share by Application (2024)
Figure 21. Global Biological Vaccines Adjuvants Revenue Market Share by Application in 2025
Figure 22. Biological Vaccines Adjuvants Sales by Company in 2025 (K Units)
Figure 23. Global Biological Vaccines Adjuvants Sales Market Share by Company in 2025
Figure 24. Biological Vaccines Adjuvants Revenue by Company in 2025 ($ millions)
Figure 25. Global Biological Vaccines Adjuvants Revenue Market Share by Company in 2025
Figure 26. Global Biological Vaccines Adjuvants Sales Market Share by Geographic Region (2020-2025)
Figure 27. Global Biological Vaccines Adjuvants Revenue Market Share by Geographic Region in 2025
Figure 28. Americas Biological Vaccines Adjuvants Sales 2020-2025 (K Units)
Figure 29. Americas Biological Vaccines Adjuvants Revenue 2020-2025 ($ millions)
Figure 30. APAC Biological Vaccines Adjuvants Sales 2020-2025 (K Units)
Figure 31. APAC Biological Vaccines Adjuvants Revenue 2020-2025 ($ millions)
Figure 32. Europe Biological Vaccines Adjuvants Sales 2020-2025 (K Units)
Figure 33. Europe Biological Vaccines Adjuvants Revenue 2020-2025 ($ millions)
Figure 34. Middle East & Africa Biological Vaccines Adjuvants Sales 2020-2025 (K Units)
Figure 35. Middle East & Africa Biological Vaccines Adjuvants Revenue 2020-2025 ($ millions)
Figure 36. Americas Biological Vaccines Adjuvants Sales Market Share by Country in 2025
Figure 37. Americas Biological Vaccines Adjuvants Revenue Market Share by Country (2020-2025)
Figure 38. Americas Biological Vaccines Adjuvants Sales Market Share byType (2020-2025)
Figure 39. Americas Biological Vaccines Adjuvants Sales Market Share by Application (2020-2025)
Figure 40. United States Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 41. Canada Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 42. Mexico Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 43. Brazil Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 44. APAC Biological Vaccines Adjuvants Sales Market Share by Region in 2025
Figure 45. APAC Biological Vaccines Adjuvants Revenue Market Share by Region (2020-2025)
Figure 46. APAC Biological Vaccines Adjuvants Sales Market Share byType (2020-2025)
Figure 47. APAC Biological Vaccines Adjuvants Sales Market Share by Application (2020-2025)
Figure 48. China Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 49. Japan Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 50. South Korea Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 51. Southeast Asia Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 52. India Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 53. Australia Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 54. ChinaTaiwan Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 55. Europe Biological Vaccines Adjuvants Sales Market Share by Country in 2025
Figure 56. Europe Biological Vaccines Adjuvants Revenue Market Share by Country (2020-2025)
Figure 57. Europe Biological Vaccines Adjuvants Sales Market Share byType (2020-2025)
Figure 58. Europe Biological Vaccines Adjuvants Sales Market Share by Application (2020-2025)
Figure 59. Germany Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 60.France Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 61. UK Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 62. Italy Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 63. Russia Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 64. Middle East & Africa Biological Vaccines Adjuvants Sales Market Share by Country (2020-2025)
Figure 65. Middle East & Africa Biological Vaccines Adjuvants Sales Market Share byType (2020-2025)
Figure 66. Middle East & Africa Biological Vaccines Adjuvants Sales Market Share by Application (2020-2025)
Figure 67. Egypt Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 68. South Africa Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 69. Israel Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 70.Turkey Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 71. GCC Countries Biological Vaccines Adjuvants Revenue Growth 2020-2025 ($ millions)
Figure 72. Manufacturing Cost Structure Analysis of Biological Vaccines Adjuvants in 2025
Figure 73. Manufacturing Process Analysis of Biological Vaccines Adjuvants
Figure 74. Industry Chain Structure of Biological Vaccines Adjuvants
Figure 75. Channels of Distribution
Figure 76. Global Biological Vaccines Adjuvants Sales MarketForecast by Region (2026-2031)
Figure 77. Global Biological Vaccines Adjuvants Revenue Market ShareForecast by Region (2026-2031)
Figure 78. Global Biological Vaccines Adjuvants Sales Market ShareForecast byType (2026-2031)
Figure 79. Global Biological Vaccines Adjuvants Revenue Market ShareForecast byType (2026-2031)
Figure 80. Global Biological Vaccines Adjuvants Sales Market ShareForecast by Application (2026-2031)
Figure 81. Global Biological Vaccines Adjuvants Revenue Market ShareForecast by Application (2026-2031)
More Publications
Global Electrodes for Medical Market Growth 2024-2030
US$ 3,660.00
September 2024
119 pages
Global Cardiac Guidewires Market Growth 2024-2030
US$ 3,660.00
November 2024
119 pages
Global Methylphenidate Drug Market Growth 2025-2031
US$ 3,660.00
October 2025
145 pages
Global Medical Camera Systems Market Growth 2024-2030
US$ 3,660.00
March 2024
112 pages
Global Genomic Biomarkers Market Growth (Status and Outlook) 2023-2029
US$ 3,660.00
February 2023
100 pages
